Drug Profile
Research programme: V 2 - Zymeworks
Alternative Names: V-2 - ZymeworksLatest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator Zymeworks
- Class Antibodies; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for research development in Colorectal-cancer in Canada
- 05 Nov 2014 Early research in Colorectal cancer in Canada (unspecified route)